Product Highlight - Wegovy

Active ingredient: Semaglutide

Indications: Adjunct to reduced-calorie diet & increased physical activity for wt management, including wt loss & maintenance, in adults w/ initial BMI of ≥30 kg/m², or ≥27 to <30 kg/m² in the presence of at least 1 wt-related comorbidity eg, dysglycaemia (prediabetes or type 2 DM), HTN, dyslipidaemia, obstructive sleep apnoea or CV disease; to reduce risk of major adverse CV events (CV death, non-fatal MI or stroke) in adults w/ established CV disease & either obese or overwt. Adjunct to reduced-calorie diet & increased physical activity for wt management in adolescents ≥12 yr w/ obesity & body wt >60 kg.

Dosage & Administration: SC Inj in the abdomen, thigh or upper arm. Dose escalation: Initially 0.25 mg once wkly (wk 1-4), increased to 0.5 mg once wkly after 4 wk (wk 5-8), then 1 mg once wkly (wk 9-12), & further increased to 1.7 mg once wkly (wk 13-16) to a maintenance dose of 2.4 mg once wkly.